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Maria B. Karpova8, Marie C. Zipser8, Cristina Muniesa9, Marı´a P. Garcı´a-Muret10, Teresa Estrach11, Marta
Salido1,3, Ju´lia Sa´nchez-Schmidt5, Marta Herrera7, Vicenc¸ Romagosa12, Javier Suela13, Bibiana I. Ferreira14,
Juan C. Cigudosa14, Carlos Barranco1, Sergio Serrano1, Reinhard Dummer8, Cornelis P. Tensen6,
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Mycosis fungoide (MF) patients who develop tumors or extracutaneous involvement usually have a poor
prognosis with no curative therapy available so far. In the present European Organization for Research and
Treatment of Cancer (EORTC) multicenter study, the genomic profile of 41 skin biopsies from tumor stage MF
(MFt) was analyzed using a high-resolution oligo-array comparative genomic hybridization platform. Seventy-six
percent of cases showed genomic aberrations. The most common imbalances were gains of 7q33.3q35 followed
by 17q21.1, 8q24.21, 9q34qter, and 10p14 and losses of 9p21.3 followed by 9q31.2, 17p13.1, 13q14.11, 6q21.3,
10p11.22, 16q23.2, and 16q24.3. Three specific chromosomal regions, 9p21.3, 8q24.21, and 10q26qter, were
defined as prognostic markers showing a significant correlation with overall survival (OS) (P¼ 0.042, 0.017, and
0.022, respectively). Moreover, we have established two MFt genomic subgroups distinguishing a stable group
(0–5 DNA aberrations) and an unstable group (45 DNA aberrations), showing that the genomic unstable group
had a shorter OS (P¼ 0.05). We therefore conclude that specific chromosomal abnormalities, such as gains of
8q24.21 (MYC) and losses of 9p21.3 (CDKN2A, CDKN2B, and MTAP) and 10q26qter (MGMT and EBF3) may have
an important role in prognosis. In addition, we describe the MFt genomic instability profile, which, to our
knowledge, has not been reported earlier.
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INTRODUCTION
Mycosis fungoides (MF) is a low-grade mature T-cell
neoplasm of malignant CD4-positive helper T lymphocytes
with a marked affinity for the skin, particularly the epidermis.
It is the most frequent type of cutaneous T-cell lymphoma
with an annual incidence close to 0.9 per 100,000
individuals in the United States (Criscione and Weinstock,
2007). MF has a long natural evolution over the years or
sometimes decades and develops in a multistep process
from patches to more infiltrated plaques and eventually
tumors (tumor stage MFs, MFt). Although patients with
patch or plaque disease normally have a long survival,
those cases developing tumors or extracutaneous involve-
ment usually have a poor prognosis with no curative therapy
available so far.
To characterize the genetic profile and to identify
prognostic markers for MFt, several comparative genomic
hybridization (CGH) studies (Karenko et al., 2003; Mao et al.,
2002; Mao et al., 2003; Fischer et al., 2004; Prochazkova
et al., 2007) have been reported. Although conventional
CGH allows the identification of chromosomal imbalances,
the identification of specific genes involved in the prognosis
remains elusive because of the low resolution of this
technique (5–10Mb). In addition, most of the prognostic
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markers in MF identified by different CGH studies have a
limited discriminatory power because of the fact that the
number of patients in this specific stage is too small.
Furthermore, the different series studied are heterogeneous
(Karenko et al., 2002; Mao et al., 2002; Mao et al., 2003;
Fischer et al., 2004), including a mixture of patients
belonging to different cutaneous lymphoma entities (MF,
Sezary syndrome (SS), primary cutaneous anaplastic large
cell lymphoma, and lymphomatoid papulosis), which actu-
ally have very different clinical outcomes making it very
difficult to analyze the prognostic implication of the results.
The development of genome-wide analysis techniques
(Solinas-Toldo et al., 1997; Pinkel et al., 1998; Pinkel and
Albertson, 2005) has allowed the characterization of more
precisely several human neoplasms with the aim of providing
prognostic markers and targets for directed therapeutic
intervention. More recently, van Doorn et al. (2009) reported
a bacterial artificial chromosome (BAC)arrayCGH study in
which genomic differences between SS and MFt were
identified. Although BACarrayCGH allows the identification
of DNA copy number changes, it does not offer a straightfor-
ward and reliable detection of small alterations because of
the larger-sized BAC probes. Thus, the identification of
specific genes that are involved could remain a challenge
(Gunnarsson et al., 2008).
The aim of this study was to analyze genetic abnormalities
in MFt patients using a 60-mer 44K oligonucleotide-
arrayCGH platform to characterize this entity in a large
series of patients. Furthermore, we evaluated whether specific
genetic alterations may provide prognostic information.
RESULTS
Array CGH results and genomic instability profile
Among the 41 MF patients, 32 (78%) showed aberrant
profiles by arrayCGH analysis, whereas no chromosomal
abnormalities were detected in nine cases (22%). All the
alterations detected are summarized in Supplementary Table
S1. Losses were more frequently observed than gains (63.3 vs
36.7%) and the mean chromosomal imbalances per case
were 3.3 gains (range 0–14) and 5.7 losses (range 0–30). The
most frequent alterations are presented in Table 1. Regarding
chromosomal aberrations, the highest frequency of gains was
detected on 7q33.3q35 followed by 17q21.1, 8q24.21,
9q34qter, and 10p14. The most frequent deletions were
observed on chromosome 9p21.3 followed by 9q31.2,
17p13.1, 13q14.11, 6q21.3, 10p11.22, 16q23.2, and
16q24.3 (Table 1). Global results are summarized in
Figure 1a. Interestingly, five homozygous deletions (HDs)
and five high-level amplifications (HLAs) have been detected.
The sizes of the aberrations mentioned and of the candidate
genes mapped in these regions are given in Supplementary
Table S2. Certain chromosomal abnormalities detected by
arrayCGH were confirmed by fluorescence in situ hybridiza-
tion (FISH) (patients 4, 8, and 29; Figure 1b).
In addition, data obtained by (Conde et al., 2007)
oligonucleotide-arrayCGH and InSilico arrayCGH software
provided a global genomic profile for MFt patients that was
analyzed in terms of genomic instability. This analysis has
allowed the segregation of MFt patients into two major
subgroups. The first subgroup, called genomically stable MFt,
included 18 cases. It was characterized by a low number of
changes (0–5), low presence of DNA breaks (DBs) (0 (0;3)),
and the absence of HLA and HD. The second group, called
genomically unstable MFt, with 23 cases, displayed a higher
number of genomic abnormalities. It was characterized by a
high number of changes (6–34), DBs (14 (10;21)), and the
presence of HLA and HD. The multiple testing between the
genomic status and the most prominent smallest overlapping
region of imbalances found in MFt patients has shown a
significant relation between the genomic status and the gain
Table 1. Summary of the most frequent prominent alterations in MFt patients
Type of change Start gene Chr Cytoband Size (Mb) % Patients Candidate genes
Gains BG495318 7 q33.3q35 14.2 55 PTN, HIPK2, BRAF, TRPV6, TRPV5, PIP, EPHA1, EZH2
Gains SMARCE1 17 q21.1 4.7 37 STAT5A, STAT5B, STAT3
Gains M13930 8 q24.21 0.75 32 MYC
Gains SLC2A8 9 q34 11 17 NOTCH, TRAF2, CARD9
Gains chr10: 004083817 10 p14 4.73 17 GATA3, IL2R
Gains chr1:195487682 1 q31.2q32.2 7.7 15 KIF14
Losses MTAP 9 p21.3 0.2 42 MTAP, CDKN2A, CDKN2B
Losses SLC35D2 9 q31.2 3.9 30 CDC14B, XPA, NR4A3
Losses DULLARD 17 p13.1 1.02 27.5 TP53, TNK1
Losses chr13:047357604 13 q14.11 2.22 20 RB
Losses CDC2L6 6 q21.3 1.2 17 No genes related to cancer
Losses chr10:031132968 10 p11.22 1.5 17 TCF8
Losses BQ189302 16 q23.2 6.7 17 CDH13
Losses ZNF469 16 q24.3 0.78 17 No genes related to cancer
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of 7q. The genomic instability profile of MFt is summarized in
Figure 2. All parameters analyzed are provided in Supple-
mentary Table S3.
Statistical analysis
The prognostic value of the genomic instability status (stable
MFt vs unstable MFt), and specific altered chromosomal
regions with a frequency higher than 15% of cases was
analyzed. In the univariate analysis, the genomically unstable
MFt group disclosed a worse prognosis (median overall
survival, OS: 88 vs 43 months; P¼ 0.05). In addition, three
specific chromosomal imbalances were associated with poor
outcome: gains/amplifications of 8q24.21 (median OS: 89.1
vs 41 months; P¼0.017), as well as deletions of 9p21.3
(median OS: 85.5 vs 45.7 months; P¼0.042) and 10q26qter
(median OS: 78 vs 19.7 months; P¼ 0.023) (Figure 3).
Besides genomic aberrations, age older than 60 (median
OS: 131.54 vs 47.5 months; P¼0.007) and multifocal
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Figure 1. Oligonucleotide arrayCGH (comparative genomic hybridization) results and fluorescence in situ hybridization (FISH) validation. (a) ArrayCGH
was applied in 41 tumor stage mycosis fungoides (MFt) frozen tissue samples and a total of 32 patients had an aberrant genomic profile. All the abnormalities
found are represented in the idiogram: the red line at the right side represents gains, whereas the green line at the left side represents losses of genomic DNA.
(b) Log2 ratio values along the chromosome are represented by a green line. The vertical line around 0 corresponds to no copy number changes. Displacement
of this green line to the left or right represents genomic losses or gains, respectively. To validate the arrayCGH results and to corroborate the gain and loss
thresholds, the fluorescence in situ hybridization (FISH) technique was applied in the paraffin-embedded tissue sections of 3 patients. All FISH results
were in concordance with those found earlier by arrayCGH.A homozygous deletion of 9p21.3 is shown here. Scale bar¼ 2 mm.
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localization of cutaneous lesions (42 presentation sites)
(median OS: 82.6 vs 39.2 months; P¼0.033) were associated
with shorter survival. No association between extracutaneous
involvement, presence of ulceration, cell size, epidermotrop-
ism, and survival was detected. The multivariate survival
analysis, taking into account the parameters considered
statistically significant by the univariate analysis, did not
reveal any independent prognostic factor (Table 2). This fact
could arise from the low number of patients. Despite this
result, it is important to mention that this study is the largest
series reported until now in MFt as it is a very infrequent
disease.
DISCUSSION
We present here a DNA genomic imbalance detailed analysis
of the largest series of MFt patients reported until now,
including 41 patients. In addition, we describe their associa-
tion with clinical data and prognosis.
Recently, van Doorn et al. (2009) have used a BACar-
rayCGH platform for the identification of genomic differences
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Figure 2. Genomic instability profile analysis and multiple testing. (a) The quantitative assay for genomic instability was performed considering the DNA breaks
(DBs)(’), whole chromosome abnormalities ( ), and the number of DBs within a chromosome ( ). It clearly distinguished between the genomic stable
subgroup on the left side of the graphic and the genomic unstable subgroup on the right side, which has a higher representation for all the analyzed parameters.
(b) Multiple testing was performed with Pomelo Cluster Tool 2.0 to compare the relationship between the genomic status and the smallest overlapping region of
imbalances found. A significant correlation between the genomic unstable tumor stage mycosis fungoides (MFt) group and the 7q regions was observed.
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between SS and MFt, describing a high frequency of gains in
chromosomes 1, 7, 8, and 17 and losses of chromosomes 5,
9, and 13. This study has allowed the detection of small
aberrations, with the smallest abnormality reported being
1.3Mb in size. With the genomic platform used in this study,
which includes about 44,000 probes covering the whole
genome at an average resolution of 75 kb, a genome-wide
analysis of a large series of MFt has been performed. Ten
cases from van Doorn et al. (2009) analysis were also
analyzed with oligonucleotide-based arrayCGH to compare
both platforms. The vast majority of the aberrations were
detected by both BACarrays and oligonucleotide-arrays.
Although the detection of gains is very similar, it is important
to emphasize that we found a higher number of losses and
that they were characterized by their smaller size. The
combination between oligo-arrays and the InSilico arrayCGH
analysis has allowed us to delineate the MFt chromosomal
alterations in more detail.
In terms of chromosomal imbalances, 78% (n¼ 32) of our
patients presented with an aberrant genomic profile. The high
rate of genetically abnormal patients could be explained by
the fact that all the patients have been studied at an advanced
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Figure 3. Impact of genomic imbalances and genomic instability groups on survival of tumor stage mycosis fungoides (MFt). A log-rank test was used to
evaluate the correlation between the genomic profile and the survival of the MFt patients. (a) The Kaplan–Meier curves showed survival differences
between genomic unstable MFt patients (dotted line) and genomic stable MFt patients. (b) Regarding specific lesions, a poor overall survival was observed in MFt
patients with 9p21.3 deletion (dotted line), (c) gains of 8q24.21 (dotted line), and (d) 10q26qter deletion (dotted line) compared with MFt patients with no
chromosomal aberrations.
Table 2. Results of the univariate and multivariate
survival analysis
Median OS
Univariate
analysis
Multivariate
analysis
Variables (n=41) (months) P-value P-value
Genetic alterations
del(9p21.3) 85 vs 46 0.04 NS
del(10q26qter) 78 vs 20 0.02 NS
+8q24.21 89 vs 41 0.02 NS
Genetic status
Stable vs Unstable 88 vs 43 0.05 NS
Clinicopathological parameters
Age (o60 vs X60 years) 131 vs 47 0.01 NS
Cutaneous localization
(localized vs multifocal)
83 vs 39 0.03 NS
NS, not significant.
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stage and therefore the proportion of malignant T-cell
lymphocytes is very high as described earlier (Mao et al.,
2003; Fischer et al., 2004; Prochazkova et al., 2007). The
nine patients who did not present genomic abnormalities
could present other altered genetic mechanisms, such as gene
mutations, methylation, aberrant miRNA expression, or
acquired uniparental disomy, which do not implicate gains
or losses of DNA. Therefore, the exploration of this type of
mechanism is necessary to elucidate other genetic alterations
that can explain the biology of this tumor. Regarding specific
alterations, losses were more frequently detected than gains
(5.7 losses vs 3.3 gains), in contrast to the recent findings by
Prochazkova et al. (2007). The analysis by Prochazkova et al.
(2007) was performed with the conventional CGH technique
(mean resolution: 5–10Mb). With this technique, gains and
losses smaller than 5Mb were not detected. In contrast, the
oligonucleotide-based array GCH platform used in this study
allowed us to detect gains and losses bigger than 75–100Kb.
This could be one reason that explains the discrepancies
between the most frequent gains and losses among the two
studies. Moreover, the sample size analyzed in this study was
bigger (41 patients vs 11 patients in Prochazkova et al. (2007)
study). However, Prochazkova et al. (2007) provided addi-
tional information regarding the DNA content (mean DNA
index 3.14±0.38), which was not analyzed in this study.
Oligonucleotide arrayCGH analysis has allowed the
description of MFt in the context of genomic instability. It
has been suggested that failures in a number of different
processes that maintain genome integrity could contribute to
the wide variety of genomic alterations in solid tumors. These
aberrations include the total gain or loss of whole chromo-
somes or parts of chromosomes, HLAs (defined as a copy
number increase of a determined region of a chromosome),
HDs (loss of the two copies of a specific region), and copy
number transitions (number of DBs within a chromosome).
Analyses of genomic instability have been reported for
bladder cancer, breast tumors, neuroblastoma, B-cell lym-
phomas, and Ewing’s tumor (Blaveri et al., 2005; Fridlyand
et al., 2006; Ferreira et al., 2008a, b). In such cases, a
correlation between highly unstable genetic profile and poor
prognosis has been shown. We have performed a quantitative
analysis of the genomic instability in MFt patients taking into
account the above mentioned parameters (Supplementary
Table S3). We observed two different groups, one genomi-
cally stable MFt characterized by a low number of
chromosomal abnormalities and the other genomically
unstable showing a high number of chromosomal abnorm-
alities. Moreover, the univariate survival analysis clearly
showed that MF patients showing a genetic unstable pattern
have a shorter survival (P¼0.05). Therefore, the rather
consistent pattern of genomic abnormalities provides reliable
information to understand the genetic bases that underlie the
clinical phenotypes of MFt with different survival rates.
Regarding specific abnormalities, we detected two aberra-
tions, 9p21.3 deletion and 8q24.21 gain, that correlate with
poor prognosis, in agreement with recently published data in
MFt patients (van Doorn et al., 2009). Our findings confirm
such results in a large series of patients and suggest the
important implication of these two regions in the pathogen-
esis of MFt patients. Regarding 9p21.3 deletion, we have
delineated a minimal region of only 200 kb comprising only
three genes CDKN2A, CDKN2B, and MTAP. Unlike the
BACarray platform used by van Doorn et al. (2009) who
detected two contiguous 9p21-deleted regions of 2Mb in
size, the oligo-arrayCGH technology has allowed the
definition in more detail of the 9p region and the genes
enclosed in these loci. Among these three genes, CDKN2A
and CDKN2B have been largely studied in MF. The most
frequent alteration has been the hypermethylation, but not
mutation, of loss of heterozygosity (Navas et al., 2000, 2002).
In this study, we have also observed a high frequency of HD,
not observed until now. On the other hand, the MTAP gene
has also been described as an important tumor suppressor
gene in several cancers (Nobori et al., 1996; Dreyling et al.,
1998; Christopher et al., 2002; Subhi et al., 2004; Marce´
et al., 2006; Worsham et al., 2006; Mirebeau et al., 2006)
and is an essential enzyme for normal activity of the adenine
and methionine synthesis. The loss of this gene is thought to
be incidental because of its proximity to CDKN2A and
CDKN2B. However, cells that lack MTAP depend on de novo
AMP synthesis and exogenous methionine supply, and are
expected to be sensitive to inhibitors of purine synthesis or
methionine starvation. A better understanding of the con-
tribution of the MTAP gene in all stages of MF could provide
an impetus for exploration of these targets as therapeutic
biomarkers in MF.
Regarding chromosome 8, partial or complete gains on 8q
have been observed in earlier studies in patients with MFt and
SS (Prochazkova et al., 2007; Vermeer et al., 2008; van
Doorn et al., 2009). In our study, we detected a high number
of patients with altered chromosome 8 and delineated a
minimal common region, 8q24.21, in 31.4% (13/41) in
concordance with recent reports (van Doorn et al., 2009). In
addition, two patients presented with an HLA of this location
involving the MYC oncogene. MYC is generally recognized as
an important regulator of proliferation, growth, differentiation,
and apoptosis (Meyer et al., 2006; Vita and Henriksson, 2006).
Interestingly, we have observed in our series a strong
correlation of this abnormality with a poor outcome of patients
(P¼ 0.017). The recent finding of gain of MYC in SS (Vermeer
et al., 2008) and MFt (van Doorn et al., 2009) and the
correlation with survival could suggest an important involve-
ment of MYC in the progression of a subset of MFt patients.
Abnormalities of chromosome 10 have been described
earlier in MFt and SS detected by G-banding cytogenetic
studies, conventional CGH, and microsatellite markers
(Limon et al., 1995; Karenko et al., 1997, 1999; Scarisbrick
et al., 2000, 2001; Mao et al., 2002, 2003; Espinet et al.,
2004; Fischer et al., 2004; Wain et al., 2005; Prochazkova
et al., 2007). We have detected 10q26qter deletion, a
minimal common region, which is to our knowledge not
reported earlier. This anomaly of only 0.7Mb in size harbors
a total of 31 genes. Among them, it is important to mention
the presence of two tumor suppressor genes: MGMT and
EBF3. Concerning the MGMT gene, its methylation status has
been studied earlier in cutaneous T-cell lymphoma (Gallardo
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et al., 2004; Van Doorn et al., 2005). However, the presence
of methylation in healthy control T-cell lymphocytes led to
the preclusion of its use as a marker of malignancy. On the
other hand, the recent description of EBF3 as a tumor
suppressor gene that induces cell cycle arrest and apoptosis
(Zhao et al., 2006) led to suggest the implication of this gene
in the pathogenesis of MFt patients. Our analysis has shown a
strong correlation between disease progression and deletion
of this region (P¼ 0.021). Thus, the genes included in
10q26qter should be studied to understand their pathogenic
role in MFt patients.
Regarding chromosome 12, an interesting region is 12q21
where NAV3 is localized. NAV3 deletions and translocations
were described as frequent genetic anomalies in MF and SS
(Karenko et al., 2005). In our study, only one patient
presented with a deletion of this region because of the loss
of the long arm of chromosome 12. Therefore, our results are
in concordance with Marty et al. (2009) who recently
described that NAV3 deletions and translocations are rare
events in cutaneous T-cell lymphoma. Moreover, a high
frequency of 12q24.31 deletions (involving BCL7a,
SMAC/DIABLO, and RHOF genes) has been reported in
early stage MF patients (Carbone et al., 2008). In contrast to
this report, we have detected a deletion in only one patient and
the loss of the entire chromosome 12 in a second one.
Therefore, the validation of this finding in a selected tumoral
population of the early stage MF biopsies would be necessary
to confirm this anomaly. Most probably, the pathogenic
mechanism related to this region in advanced stage patients
was the hypermethylation of the tumor suppressor gene BCL7a,
as reported earlier in cutaneous T-cell lymphoma patients (Van
Doorn et al., 2005), but not the deletion of this area.
Among all the alterations detected in this analysis, we
have observed that some of them are very similar to SS
(Vermeer et al., 2008), such as gains of 17q21.1 and 8q24.21
and losses of 17p13.1 and 10p11.2. Although we have
detected these alterations in less proportion and the vast
majority of alterations are quite different, it is important to
remark that among the three patients who presented with
blood involvement, all of them had a loss of 17p13.1 and
gain of 17q21.1 , and one of them presented with a loss of
10p11.22 and the another one with a gain of 8q24.21. Our
findings support that Se´zary syndrome patients have a
different genomic profile than do MFt patients (van Doorn
et al., 2009). However, the presence of similar aberrations in
MFt patients who present with blood involvement seems to
indicate that both pathologies have a similar origin. More
studies comparing these two groups of patients (SS de novo vs
SS with an earlier MF) will provide additional information of
these entities.
In summary, oligonucleotide-based arrayCGH analyses
have clearly shown a high frequency of genetic imbalances
and chromosomal abnormalities, not reported earlier to our
knowledge in MFt, which provide a strictly genomic
characterization of this entity. Moreover, we report the
genomic profile of MFt patients in terms of genetic instability,
which is to our knowledge not reported earlier, categorizing
the patients into two MFt genomic subgroups: a stable group
(0–5 DNA aberrations) and an unstable group (45 DNA
aberrations). Furthermore, the correlation of the genomic
status, as well as the deletion of 9p21.3 and 10q26qter and
gain of 8q24.21 with the outcome, offers the possibility of
selecting these patients to precisely adjust their clinical
management. The detection of these alterations with routine
techniques such as FISH and/or multiplex ligation-dependent
probe amplification during the follow-up could be used to
closely monitor this group of patients to identify particular
subsets presenting a more aggressive clinical evolution.
Validation of such genomic features represents a reasonable
next step for the definition of biological prognostic factors
enabling the design of optimized risk-adapted treatment
strategies.
MATERIALS AND METHODS
Patients
A total of 41 patients collected from centers collaborating in the
European Organization for Research and Treatment of Cancer
(EORTC) Cutaneous Lymphoma Group were included in the study.
They comprised 22 males and 19 females with a mean age of 59
years (range, 17–84 years). All patients were diagnosed according to
the World Health Organization (WHO)-EORTC classification for
cutaneous lymphoma criteria (Willemze et al., 2005; Olsen et al.,
2007). Clinical and follow-up data are summarized in Tables 2 and
3. Ten patients were earlier studied using a BACarrayCGH platform
(van Doorn et al., 2009). The approval for the study was provided by
the Comite` E`tic d0Investigacio´ Clı´nica from l0Institut Municipal
d0Assiste`ncia Sanita`ria (CEIC-IMAS) and written informed consent
was obtained from all patients, according to the Declaration of
Helsinki Principles.
DNA extraction
To ensure the high quality of the DNA analyzed, 20 10 mm snap-
frozen samples from tumoral MF lesions were included in the study.
A hematoxylin-eosin staining of a frozen section from all cases was
performed earlier to confirm the presence of at least 70% of tumor
cells. DNA was isolated using a commercial kit, as described
(DNeasy Blood & Tissue Kit; Qiagen, Hilden, Germany).
Array CGH
Genome-wide analysis of patient samples was conducted using the
Human Genome CGH 44K microarrays (G4410B and G4426B)
(Agilent Technologies, Palo Alto, CA). The hybridization process was
performed according to the manufacturer’s protocols. Commercial
pools of healthy female DNA (Promega, Madison, WI) were used as
controls. For extraction of raw data and visualization of results,
Feature Extraction v.8.1 and CGH Analytics v3.2.25 softwares were
used (Agilent Technologies). Data analysis and chromosome
segmentation were performed with InSilico Array CGH software
smoothing methods (Conde et al., 2007) included in GEPAS (http://
gepas.bioinfo.cipf.es). This software provided a copy number value
that allowed the establishment of cutoff values at 0.3 and 0.5 for
considering gains and losses, respectively. For HLAs and HDs, the
cutoff values were set at 0.6 and 1, respectively. Recurrent regions
involved in genomic imbalances were defined as a sequence of at
least five consecutive altered probes common to a set of array CGH
profiles and the smallest overlapping region of imbalance as the
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minimal common region detected in at least two patients (Rouveirol
et al., 2006). Genomic aberrations in known copy number
polymorphisms were not considered as alterations.
Moreover, we have applied a genomic stability assay to evaluate
the genetic status of this type of tumor. Total gain or loss of whole
chromosomes or parts of chromosomes, HLAs (defined as a copy
number increase of a determined region of a chromosome), HDs,
and copy number transitions (the number of DBs within a
chromosome) were quantified (Supplementary Table S3). A multiple
testing tool (Pomelo Cluster; http://pomelo.bioinfo.cnio.es) was used
to compare the genomic MFt patient status with all smallest
overlapping region of imbalances found applying Fisher’s test.
Fluorescence in situ hybridization
Fluorescence in situ hybridization was performed to confirm
chromosomal abnormalities detected earlier by arrayCGH in those
cases in which a paraffin-embedded tissue biopsy was available. The
FISH probes used are summarized in Supplementary Table S4.
Statistical analysis
Overall survival was calculated as the time elapsed from the first
date of diagnosis of MFs to death of the lymphoma or to last follow-
up. The Kaplan–Meier method was used to estimate the distribution
of OS. Differences in survival between groups were assessed using
the log-rank test. Multivariate Cox proportional hazards regression
was performed. The following clinical, morphological, and genetic
parameters were evaluated to identify risk factors in a univariate
analysis for OS: age (o60 years against460 years), sex, localization
of cutaneous lesions, extracutaneous involvement, response to
therapy, presence of large cells, genomic instability status, and
presence of recurrent genomic abnormalities (more than 15% of
cases). For comparison of two groups, the Mann–Whitney U-test and
Pearson w2-test were used. Statistical computations were performed
using the SPSS v.15 software (SPSS, Chicago, IL). A P-value ofp0.05
was considered statistically significant.
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